BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age35-44
SponsorCentrum Clinic IVF Center
About this trial
This observational clinical study aims to determine the optimal timing of ovulation triggering in women aged 35 and above with poor ovarian reserve.
For this purpose, cases undergoing ovarian stimulation for assisted reproductive treatment and planned final oocyte triggering will be evaluated in two separate groups:
1. \*\*Experimental Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm. 2. \*\*Control Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.
All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.
The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.
Primary and secondary outcomes will be compared between the two groups.
Eligibility criteria
Qualifiers
Women age equal to or greater than 35 years
Women with low serum AMH (<1,2 ng/ml),
women with low AFC (<5)
women Undergoing assisted reproduction with Short antagonist protocol or long -agonist protocol
Disqualifiers
Age <35 years.
Ovarian reserve parameters not meeting the POSEIDON group 4 definition.
Natural or modified natural cycles without controlled ovarian stimulation.
In vitro maturation (IVM) cycles.
Trial design
Treatments tested in this trial
- Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov